Dmitry Bandura

[1][2] Bandura co-founded DVS Sciences[3] in 2004 (acquired by Fluidigm in 2014 and then renamed to Standard BioTools[4] in 2022) along with Drs Vladimir Baranov, Scott D. Tanner, and Olga Ornatsky.

His PhD thesis research focused on elemental analysis of hypervelocity microparticles via time-of-flight mass spectrometry (TOF-MS) of their impact-induced plasma.

[8] There, he worked on the development of inductively coupled plasma mass spectrometry (ICP-MS),[7] contributing to the release of the award-winning Optimass 8000 ICP-TOF-MS in 1998.

[9] In 2005, together with Scott D. Tanner and Vladimir Baranov, Bandura began independently developing an ICP-TOF-MS based cytometer and became a researcher at the University of Toronto in March 2005.

[10] After securing ample funding by 2010 from various sources, including National Institutes of Health, Ontario Institute for Cancer Research (OICR), the Ministry of Research and Innovation, Ontario Centres of Excellence, Health Technology Exchange, and Genome Canada via the Ontario Genomics Institute,[11][12][3] and venture capital from 5 AM Ventures,[13] Bandura and the DVS Sciences team successfully commercialized their technology, leading to the acquisition of DVS Sciences by Fluidigm in 2014[14] Bandura headed R&D and Canadian operations at Fluidigm Canada following the merger and Standard BioTools Canada (formerly DVS Sciences) following a capital infusion in 2022,[15] stewarding the development of the next generation of mass cytometry and imaging mass cytometry instruments and reagents.